Utilities Down as Fed's Powell Voices Rate-Cut Doubts — Utilities Roundup
Shares of power producers declined as traders braced for a shift in Federal Reserve rate-cutting plans.
Fed Chairman Jerome Powell warned that recent data could force a reconsideration of the central bank's policy intentions. In recent weeks, the odds of a rate cut in June have fallen significantly, and strategists are now questioning whether any rate cuts will occur in 2024 at all.
"I was always in the camp we may see one or two [rate cuts]," said Joe Rinaldi, president and chief investment officer at wealth manager Quantum Financial Advisors. "Most likely you'll see one right before the election around September ... I think we'll see a choppy market from May through September."
Write to Rob Curran at rob.curran@dowjones.com
(END) Dow Jones Newswires
April 16, 2024 18:15 ET (22:15 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.-
5 Undervalued Stocks to Buy to Play a Little Defense
-
Markets Brief: AI Leaders Excel In Earnings Season So Far
-
What History Tells Us About the Fed’s Next Move
-
What’s Happening In the Markets This Week
-
Alphabet’s New Dividend: What Investors Need to Know
-
Going Into Earnings, Is Palantir Stock a Buy, a Sell, or Fairly Valued?
-
Going Into Earnings, Is Eli Lilly Stock a Buy, a Sell, or Fairly Valued?
-
What’s the Difference Between the CPI and PCE Indexes?
-
After Earnings, Is Tesla Stock a Buy, a Sell, or Fairly Valued?
-
After Earnings, Is GE Aerospace Stock a Buy, a Sell, or Fairly Valued?
-
3 Good Stocks to Buy with Your Tax Refund in 2024 (Or with Any Extra Money)
-
SoFi Earnings: Revenue Growth Slows on Lower Loan Growth and Higher Credit Costs
-
Tesla: Full Self-Driving Approval In China Supports Our View for Deliveries Growth In 2024
-
Philips Earnings: Firm Reaches $1.1 Billion Settlement Agreement
-
AbbVie Earnings: Next-Generation Immunology Drugs Help Offset Humira Biosimilar Pressure
-
Exxon Earnings: Ignore Earnings Shortfall as Long-Term Growth and Improvement on Track